OverviewSuggest Edit

Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. It develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER).

TypePublic
HQTübingen, DE
Websiteimmatics.com

Latest Updates

Employees (est.) (Dec 2020)230
Job Openings10
Revenue (FY, 2020)€31.3 M(+70%)
Share Price (Jul 2021)$12.6(+4%)
Cybersecurity ratingCMore

Key People/Management at Immatics

Peter Chambré

Peter Chambré

Chairman
Harpreet Singh

Harpreet Singh

Chief Executive Officer
Arnd Christ

Arnd Christ

Chief Financial Officer
Carsten Reinhardt

Carsten Reinhardt

Chief Development Officer
Arun Satelli

Arun Satelli

Director of Target-Based Biomarkers
Cedrik Britten

Cedrik Britten

Chief Medical Officer
Show more

Immatics Office Locations

Immatics has offices in Tübingen, München and Houston
Tübingen, DE (HQ)
Paul-Ehrlich-Str. 15
München, DE
Machtlfinger Str. 11
Houston, TX, US
2201 W Holcombe Blvd #205
Show all (3)

Immatics Financials and Metrics

Immatics Revenue

Immatics's revenue was reported to be €31.25 m in FY, 2020 which is a 69.4% increase from the previous period.
EUR

Revenue (FY, 2020)

31.3m

Revenue growth (FY, 2019 - FY, 2020), %

69.4%

Net income (FY, 2020)

(229.6m)

EBIT (FY, 2020)

(69.7m)

Market capitalization (22-Jul-2021)

790.1m

Closing stock price (22-Jul-2021)

12.6

Cash (31-Dec-2020)

207.5m

EV

588.8m
Immatics's current market capitalization is $790.1 m.
Annual
EURFY, 2018FY, 2019FY, 2020

Revenue

3.8m18.4m31.3m

Revenue growth, %

389%69%

General and administrative expense

7.7m11.8m34.2m

R&D expense

34.0m40.1m67.1m
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

3.6m5.4m5.1m7.0m6.9m7.9m

General and administrative expense

2.3m2.1m2.8m6.2m10.1m9.2m

R&D expense

8.0m9.7m10.2m12.2m16.5m17.5m

Operating expense total

10.3m11.8m13.0m18.4m26.6m26.7m
Annual
EURFY, 2018FY, 2019FY, 2020

Cash

39.4m103.4m207.5m

Accounts Receivable

393.0k957.0k1.3m

Current Assets

55.3m124.0m239.0m

PP&E

4.0m4.7m7.9m
Quarterly
EURQ1, 2020Q2, 2020Q3, 2020

Cash

72.2m86.1m233.7m

Accounts Receivable

332.0k427.0k1.0m

Current Assets

109.7m92.1m266.9m

PP&E

6.0m6.7m7.8m
Annual
EURFY, 2018FY, 2019FY, 2020

Net Income

(32.4m)(32.5m)(229.6m)

Depreciation and Amortization

2.2m3.9m4.4m

Accounts Payable

43.7m98.9m(23.4m)

Cash From Operating Activities

7.6m68.0m(85.6m)
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(5.9m)(12.6m)(17.5m)(8.6m)(29.9m)(207.0m)

Depreciation and Amortization

948.0k1.9m2.8m1.0m2.3m3.5m

Accounts Payable

(4.4m)(8.1m)56.7m(4.8m)(9.7m)(16.0m)

Cash From Operating Activities

(248.0k)(5.0m)42.4m(28.3m)(11.7m)(59.9m)
EURFY, 2018

Revenue/Employee

37.2k

Financial Leverage

-6.7 x
Show all financial metrics

Immatics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Immatics Online and Social Media Presence

Embed Graph

Immatics News and Updates

BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions

BASEL, Switzerland and TÜBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human...

Immatics Announces First Quarter 2021 Financial Results and Business Update

Tuebingen, Germany and Houston, TX, May 18, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarte…

Immatics Announces Full Year 2020 Financial Results and Corporate Update

Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial re…

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

 Company to host conference call on Wednesday, March 17 at 8:30 am EST

Immatics Announces Third Quarter 2020 Financial Results and Business Update

Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarter ended September 30, 2020.
Show more

Immatics Frequently Asked Questions

  • Who are Immatics key executives?

    Immatics's key executives are Peter Chambré, Harpreet Singh and Arnd Christ.

  • How many employees does Immatics have?

    Immatics has 230 employees.

  • What is Immatics revenue?

    Latest Immatics annual revenue is €31.3 m.

  • What is Immatics revenue per employee?

    Latest Immatics revenue per employee is €135.9 k.

  • Who are Immatics competitors?

    Competitors of Immatics include Eureka Therapeutics, Tessa Therapeutics and Juno Therapeutics.

  • Where is Immatics headquarters?

    Immatics headquarters is located at Paul-Ehrlich-Str. 15, Tübingen.

  • Where are Immatics offices?

    Immatics has offices in Tübingen, München and Houston.

  • How many offices does Immatics have?

    Immatics has 3 offices.